<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04857632</url>
  </required_header>
  <id_info>
    <org_study_id>STATIC</org_study_id>
    <nct_id>NCT04857632</nct_id>
  </id_info>
  <brief_title>Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage</brief_title>
  <acronym>STATIC</acronym>
  <official_title>Statin for Neuroprotection in Spontaneous Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain injury after spontaneous intracerebral hemorrhage results from pathophysiologic&#xD;
      responses in the brain parenchyma due to hematoma formation, release of clot components, and&#xD;
      surrounding edema. Inflammatory cascade activation in the perihematomal brain parenchyma has&#xD;
      been implicated in the pathogenesis of secondary brain injury. Statins have been identified&#xD;
      as a potential neuroprotective agent that targets the inflammatory response to intracerebral&#xD;
      hemorrhage. In preclinical studies, statin treatment in animal intracerebral hemorrhage&#xD;
      models has consistently demonstrated neuroprotective and recovery enhancement effects.&#xD;
      Clinical investigations in humans reported better patient outcomes associated with statin use&#xD;
      in patients with intracerebral hemorrhage, including reduced perihematomal edema, lower&#xD;
      mortality rates, and improved functional outcomes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Perihemorrhagic edema to hematoma ratio</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute perihematomal edema changes</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematoma resolution rate</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute hematoma volume changes</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ordinal distribution of modified Rankin scale scores</measure>
    <time_frame>90 days</time_frame>
    <description>The modified Rankin scale is a 7-point scale ranging from 0 (no symptoms) to 6 (death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin scale score 0-2</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with modified Rankin scale score 0-3</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>30 dyas</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Institute of Health stroke scale</measure>
    <time_frame>7 days or discharge</time_frame>
    <description>Scores on the National Institutes of Health Stroke Scale range from 0 to 42, with higher scores indicating more severe neurologic deficits.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <condition>Statins</condition>
  <arm_group>
    <arm_group_label>Statins group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>atorvastatin 20mg per day for 7 days</description>
    <arm_group_label>Statins group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 years or older&#xD;
&#xD;
          -  A clinical diagnosis of supratentorial intracerebral hemorrhage is confirmed by brain&#xD;
             CT scan&#xD;
&#xD;
          -  Hematoma volume ≤40ml&#xD;
&#xD;
          -  The first dose of statin can be given within 24h of intracerebral hemorrhage symptom&#xD;
             onset (if the patient is randomized to statin group)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of intraventricular hemorrhage or subarachnoid hemorrhage&#xD;
&#xD;
          -  Planned surgical hematoma evacuation by open craniotomy prior to randomization&#xD;
             (planned minimally invasive surgery is not a contraindication to enrollment)&#xD;
&#xD;
          -  Suspected secondary intracerebral hemorrhage related to trauma, tumor, ruptured&#xD;
             aneurysm or arteriovenous malformation, hemorrhagic transformation of an ischemic&#xD;
             infarct, Moyamoya disease, or venous sinus thrombosis&#xD;
&#xD;
          -  Unable to swallow a statin pill and have contraindication to position a nasogastric&#xD;
             tube&#xD;
&#xD;
          -  Active liver disease or hepatic dysfunction, defined as aspartate aminotransferase&#xD;
             (AST), or alanine aminotransferase (ALT) ≥2 × the upper limit of normal&#xD;
&#xD;
          -  Known pregnancy, or positive pregnancy test, or breastfeeding&#xD;
&#xD;
          -  Other diseases or abnormalities that the investigator believed might compromise the&#xD;
             patient's safety during the study&#xD;
&#xD;
          -  Historical modified Rankin scale score ≥2&#xD;
&#xD;
          -  Life expectancy of less than 7 days&#xD;
&#xD;
          -  Participation in another clinical study within 30 days prior to screening for the&#xD;
             present study&#xD;
&#xD;
          -  Prior use of statins within 1 month before intracerebral hemorrhage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Age of 18 years or older</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chuanjie Wu, Dr.</last_name>
    <phone>18911366882</phone>
    <email>wuchuanjie8557@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Fengtai Youanmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daiquan Gao, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuan Wu Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xunming ji</last_name>
      <phone>861013120136877</phone>
      <email>jixunming@vip.163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Ji Xunming,MD,PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

